Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Affymetrix Charts. Click Here for more Affymetrix Charts.](/p.php?pid=staticchart&s=N%5EAFFX&p=8&t=15)
Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a
five-year collaboration with the Peter MacCallum Cancer Centre (Peter
Mac) in Melbourne, Australia, to analyze genomic information across
large patient samples. Under terms of the agreement, Peter Mac
researchers will use Affymetrix GeneChip®
microarray technology for translational research projects, beginning
with studies on ovarian cancer and carcinoma of unknown primaries.
Peter Mac researchers will use Affymetrix GeneChip technology to perform
large-scale clinical studies. The Affymetrix technology will enable them
to more rapidly discover RNA and DNA patterns that can better classify,
manage and treat complex diseases.
“We are excited about the opportunities
created by the Translational Medicine Program, particularly the chance
to apply new technologies to help us answer important clinical questions,”
said Professor David Bowtell, Ph.D., director of research at the Peter
MacCallum Cancer Centre. “We are keen to help
our collaborators across Australia gain access to Affymetrix technology,
as we continue to develop as a major center for cancer genomics and
genetics. We also see the program providing opportunities to interact
with other centers worldwide that are involved in translational research.”
To watch the full Affymetrix UserForum interview with Professor Bowtell,
please visit: http://www.affymetrix.com/userForum/news/collaborations/bowtell.uf
“Affymetrix is excited to be working with a
leading research organization such as the Peter MacCallum Cancer Centre
to help bring more effective personalized tests and therapies to market
faster,” said Robert Wells, vice president,
International Markets Group and Corporate Affairs at Affymetrix. “Together,
we hope to accelerate clinical research, improve patient care, and open
the door to new genomic applications.”
Affymetrix collaborates with academic institutions, advocacy groups and
the pharmaceutical and diagnostics community through its
Translational Medicine Program to develop molecular signatures for
improving patient care. Affymetrix GeneChip microarray technology helps
researchers to diagnose and tailor treatments for individual patients by
identifying and measuring the genetic information associated with
complex diseases. The Translational Medicine Program complements the
Powered by Affymetrix™ program, which enables
companies to license GeneChip technology to create innovative,
custom-designed microarray products based on signatures such as those of
our translational medicine partners. This technology is already being
used in many applications, including diagnostics, forensics, animal,
industrial and food testing.
Millennium Science Pty. Ltd. will supply the Affymetrix microarray
technology and provide technical support to the Peter Mac Cancer Centre.
Since being founded in 1999, Millennium Science has grown into a leading
distributor of instrumentation and reagents for the biotechnology
research and industrial markets across Australia and New Zealand.
About Peter MacCallum Cancer Centre
As Australia’s foremost cancer centre, Peter
Mac provides quality treatment and support to patients and their
families. Underpinned by research and the best evidence available, Peter
Mac broadly influences cancer care in the community through
multi-disciplinary partnerships, research and education.
The Research Division is located at Peter Mac, East Melbourne. Peter Mac
Research employs nearly 300 staff, making it not only Australia's
largest, but also one of the world's largest groups dedicated to cancer
research. Research in the Division is undertaken within the broad
framework of research programs in Cellular
& Molecular Biology, Cancer
Immunology and Cancer
Genomics & Genetics. The latter program is home to several large
collaborative cancer studies, including kConFab, which focuses on
familial breast cancer, and the Australian Ovarian Cancer Study.
About Affymetrix
Affymetrix scientists invented the world's first high-density microarray
in 1989 and began selling the first commercial microarray in 1994. Since
then, Affymetrix GeneChip®
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research institutes.
More than 1,400 systems have been installed around the world and more
than 7,000 peer-reviewed papers have been published using the
technology. Affymetrix' patented photolithographic manufacturing process
provides the most information capacity available today on an array,
enabling researchers to use a whole-genome approach to analyzing the
relationship between genetics and health. Affymetrix is headquartered in
Santa Clara, Calif., with manufacturing facilities in Sacramento,
Calif., and Bedford, Mass. The company maintains important sales and
marketing operations in Europe and Asia and has about 1,100 employees
worldwide. For more information about Affymetrix, please visit the
company's website at www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected, including, but not limited to: risks
and uncertainties associated with the outcome of the collaboration with
the Peter MacCallum Cancer Centre discussed in this press release; risks
of the Company's ability to achieve and sustain higher levels of
revenue, higher gross margins, reduced operating expenses; uncertainties
relating to technological approaches, manufacturing, product
development; personnel retention; uncertainties related to cost and
pricing of Affymetrix products; dependence on collaborative partners;
uncertainties relating to sole source suppliers; uncertainties relating
to FDA and other regulatory approvals; competition; risks relating to
intellectual property of others and the uncertainties of patent
protection and litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other
SEC reports, including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
Affymetrix' expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.
Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered
into a five-year collaboration with the Peter MacCallum Cancer Centre
(Peter Mac) in Melbourne, Australia, to analyze genomic information
across large patient samples. Under terms of the agreement, Peter Mac
researchers will use Affymetrix GeneChip(R) microarray technology for
translational research projects, beginning with studies on ovarian
cancer and carcinoma of unknown primaries.
Peter Mac researchers will use Affymetrix GeneChip technology to
perform large-scale clinical studies. The Affymetrix technology will
enable them to more rapidly discover RNA and DNA patterns that can
better classify, manage and treat complex diseases.
"We are excited about the opportunities created by the
Translational Medicine Program, particularly the chance to apply new
technologies to help us answer important clinical questions," said
Professor David Bowtell, Ph.D., director of research at the Peter
MacCallum Cancer Centre. "We are keen to help our collaborators across
Australia gain access to Affymetrix technology, as we continue to
develop as a major center for cancer genomics and genetics. We also
see the program providing opportunities to interact with other centers
worldwide that are involved in translational research."
To watch the full Affymetrix UserForum interview with Professor
Bowtell, please visit:
http://www.affymetrix.com/userForum/news/collaborations/bowtell.uf
"Affymetrix is excited to be working with a leading research
organization such as the Peter MacCallum Cancer Centre to help bring
more effective personalized tests and therapies to market faster,"
said Robert Wells, vice president, International Markets Group and
Corporate Affairs at Affymetrix. "Together, we hope to accelerate
clinical research, improve patient care, and open the door to new
genomic applications."
Affymetrix collaborates with academic institutions, advocacy
groups and the pharmaceutical and diagnostics community through its
Translational Medicine Program to develop molecular signatures for
improving patient care. Affymetrix GeneChip microarray technology
helps researchers to diagnose and tailor treatments for individual
patients by identifying and measuring the genetic information
associated with complex diseases. The Translational Medicine Program
complements the Powered by Affymetrix(TM) program, which enables
companies to license GeneChip technology to create innovative,
custom-designed microarray products based on signatures such as those
of our translational medicine partners. This technology is already
being used in many applications, including diagnostics, forensics,
animal, industrial and food testing.
Millennium Science Pty. Ltd. will supply the Affymetrix microarray
technology and provide technical support to the Peter Mac Cancer
Centre. Since being founded in 1999, Millennium Science has grown into
a leading distributor of instrumentation and reagents for the
biotechnology research and industrial markets across Australia and New
Zealand.
About Peter MacCallum Cancer Centre
As Australia's foremost cancer centre, Peter Mac provides quality
treatment and support to patients and their families. Underpinned by
research and the best evidence available, Peter Mac broadly influences
cancer care in the community through multi-disciplinary partnerships,
research and education.
The Research Division is located at Peter Mac, East Melbourne.
Peter Mac Research employs nearly 300 staff, making it not only
Australia's largest, but also one of the world's largest groups
dedicated to cancer research. Research in the Division is undertaken
within the broad framework of research programs in Cellular &
Molecular Biology, Cancer Immunology and Cancer Genomics & Genetics.
The latter program is home to several large collaborative cancer
studies, including kConFab, which focuses on familial breast cancer,
and the Australian Ovarian Cancer Study.
About Affymetrix
Affymetrix scientists invented the world's first high-density
microarray in 1989 and began selling the first commercial microarray
in 1994. Since then, Affymetrix GeneChip(R) technology has become the
industry standard in molecular biology research. Affymetrix technology
is used by the world's top pharmaceutical, diagnostic and
biotechnology companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have been
installed around the world and more than 7,000 peer-reviewed papers
have been published using the technology. Affymetrix' patented
photolithographic manufacturing process provides the most information
capacity available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between genetics
and health. Affymetrix is headquartered in Santa Clara, Calif., with
manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The
company maintains important sales and marketing operations in Europe
and Asia and has about 1,100 employees worldwide. For more information
about Affymetrix, please visit the company's website at
www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding
Affymetrix' "expectations," "beliefs," "hopes," "intentions,"
"strategies," or the like. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially for
Affymetrix from those projected, including, but not limited to: risks
and uncertainties associated with the outcome of the collaboration
with the Peter MacCallum Cancer Centre discussed in this press
release; risks of the Company's ability to achieve and sustain higher
levels of revenue, higher gross margins, reduced operating expenses;
uncertainties relating to technological approaches, manufacturing,
product development; personnel retention; uncertainties related to
cost and pricing of Affymetrix products; dependence on collaborative
partners; uncertainties relating to sole source suppliers;
uncertainties relating to FDA and other regulatory approvals;
competition; risks relating to intellectual property of others and the
uncertainties of patent protection and litigation. These and other
risk factors are discussed in Affymetrix' Form 10-K/A for the year
ended December 31, 2005, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix'
expectations with regard thereto or any change in events, conditions
or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.